Posted by Michael Wonder on 15 Jun 2026
Oncopeptides submits type II variation application to EMA for Pepaxti label expansion into third-line treatment
12 June 2026 - Oncopeptides today announces that it has formally submitted its type II variation application to the EMA.
The application has been successfully validated, and the official regulatory procedure is scheduled to start on 20 June 2026.
